Taking ‘patient’ approach, Frazier preparing to write bigger checks from new $987M fund

As Frazier prepares to invest its eleventh and largest fund across a spectrum of private and public life sciences companies, the firm’s Jamie Topper is optimistic that a cyclical return to stability is due for the sector sooner or later.

Frazier Healthcare Partners said Wednesday it had closed its Fund XI at $987 million, about 60% larger than its 2020-vintage tenth flagship fund and well over twice the size of its $419 million Fund IX, closed in 2017. Topper told BioCentury that Frazier hopes to make bigger investments in some of its portfolio companies with the new vehicle, as well as stretching to a fund cycle closer to three years than two...